An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514969-18-00

Acronym

BLU-285-2404

Enrollment

Registered

2024-10-08

Start date

2024-11-05

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Mastocytosis

Brief summary

no primary end points

Interventions

DRUGAvapritinib

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
no primary end points	—

Countries

Belgium, Italy, Netherlands, Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026